Publication & Citation Trends
Publications
0 total
Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies
Cited by 0
Semantic Scholar
Intralesional Cemiplimab for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma: Results From a Phase 1 Pilot Study Expansion Cohort
Cited by 0
Semantic Scholar
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Cited by 17
Semantic Scholar
Patient-reported outcomes (PROs) in the C-POST trial of adjuvant cemiplimab (cemi) vs placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).
Cited by 0
Semantic Scholar
Abstract LB366: Fianlimab + cemiplimab in patients (pts) with advanced (adv) melanoma (Mel): Subgroup analyses by blinded independent central review (BICR)
Cited by 0
Semantic Scholar
Trial in progress: A phase 3 randomized study of low-dose intralesional cemiplimab versus primary surgery for patients with early-stage cutaneous squamous cell carcinoma (CLEAR CSCC).
Cited by 1
Semantic Scholar
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer
Cited by 3
Semantic Scholar
A phase 2 study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus cemiplimab plus placebo in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with positive PD-L1 expression.
Cited by 0
Semantic Scholar
Research Topics
Nonmelanoma Skin Cancer Studies
(74)
Cancer Immunotherapy and Biomarkers
(67)
Head and Neck Cancer Studies
(61)
CAR-T cell therapy research
(50)
Lung Cancer Treatments and Mutations
(45)
Affiliations
Memorial Sloan Kettering Cancer Center
The University of Texas MD Anderson Cancer Center
Hallym University
Eli Lilly (United States)
Regeneron (United States)